Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).

Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.

Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses evolving options in first line treatment of ALK-Positive non-small cell lung cancer (NSCLC).

Lung Cancer Video Library - Utility of Liquid Biopsies with Dr. Charu Aggarwal

For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer.In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. To join the conversation, visit https://cancergrace.org

GRACE is excited to bring you a new series on current updates in Melanoma TreatmentMeredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment.Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chiefof Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

2020 MELANOMA Updates - Current Status of Sentinel Lymph Node Mapping & Completion Lymphadenectomy

GRACE is excited to bring you a new series on current updates in Melanoma Treatment.Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

2020 MELANOMA - Is there a Role for Molecular Testing in Early Melanoma Management

GRACE is excited to bring you a new series on current updates in Melanoma Treatment.Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

2020 MELANOMA - Future Prospects for Immunotherapy Agents in Advanced Melanoma

GRACE is excited to bring you a new series on current updates in Melanoma Treatment.Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

2020 MELANOMA - Understanding Immunotherapy Resistance Mechanisms in Melanoma

GRACE is excited to bring you a new series on current updates in Melanoma Treatment.Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

2020 MELANOMA - What is the Correct Choice for First Line Therapy for BRAF Positive Metastatic Melanoma

GRACE is excited to bring you a new series on current updates in Melanoma Treatment.Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University